Difference between revisions of "Apalutamide (Erleada)"
m |
m |
||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2018-02-14: [https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm596768.htm FDA approved] for patients with non-metastatic castration-resistant [[prostate cancer]] (NM-CRPC). ''(Based on SPARTAN)'' |
| − | * | + | *2019-09-17: Approved for patients with metastatic castration-sensitive [[prostate cancer]] (mCSPC). ''(Based on TITAN<sub>prostate</sub>)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2019-01-14: Initial marketing authorization as Erleada. |
| + | ==History of changes in Health Canada indication== | ||
| + | *2018-07-03: Initial notice of compliance for the treatment of patients with non-metastatic castration-resistant [[prostate cancer]] at high risk of developing metastases. | ||
| + | *2019-12-12: New indication | ||
==Also known as== | ==Also known as== | ||
| Line 38: | Line 41: | ||
[[Category:EMA approved in 2019]] | [[Category:EMA approved in 2019]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
| + | [[Category:Health Canada approved in 2018]] | ||
Revision as of 00:32, 2 April 2023
General information
Class/mechanism: Antiandrogen; androgen receptor inhibitor (ARI). Apalutamide competitively inhibits activity mediated by the androgen receptor (AR) by binding directly to the AR ligand-binding domain, nuclear translocation, DNA binding, and AR-mediated transcription. A metabolite of apalutamide,
N-desmethyl apalutamide, also exhibits some AR inhibiting activity, about 1/3 that of apalutamide.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Apalutamide (Erleada) package insert[1]
- Apalutamide (Erleada) patient drug information (Chemocare)[4]
- Apalutamide (Erleada) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2018-02-14: FDA approved for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). (Based on SPARTAN)
- 2019-09-17: Approved for patients with metastatic castration-sensitive prostate cancer (mCSPC). (Based on TITANprostate)
History of changes in EMA indication
- 2019-01-14: Initial marketing authorization as Erleada.
History of changes in Health Canada indication
- 2018-07-03: Initial notice of compliance for the treatment of patients with non-metastatic castration-resistant prostate cancer at high risk of developing metastases.
- 2019-12-12: New indication
Also known as
- Code name: ARN-509
- Brand name: Erleada